324 related articles for article (PubMed ID: 32069220)
1. DIAGNOSIS OF ENDOCRINE DISEASE: Mosaic disorders of FGF23 excess: Fibrous dysplasia/McCune-Albright syndrome and cutaneous skeletal hypophosphatemia syndrome.
de Castro LF; Ovejero D; Boyce AM
Eur J Endocrinol; 2020 May; 182(5):R83-R99. PubMed ID: 32069220
[TBL] [Abstract][Full Text] [Related]
2. Expression of FGF23 is correlated with serum phosphate level in isolated fibrous dysplasia.
Kobayashi K; Imanishi Y; Koshiyama H; Miyauchi A; Wakasa K; Kawata T; Goto H; Ohashi H; Koyano HM; Mochizuki R; Miki T; Inaba M; Nishizawa Y
Life Sci; 2006 Apr; 78(20):2295-301. PubMed ID: 16337659
[TBL] [Abstract][Full Text] [Related]
3. Choosing the Best Tissue and Technique to Detect Mosaicism in Fibrous Dysplasia/McCune-Albright Syndrome (FD/MAS).
Vado Y; Manero-Azua A; Pereda A; Perez de Nanclares G
Genes (Basel); 2024 Jan; 15(1):. PubMed ID: 38255009
[No Abstract] [Full Text] [Related]
4. Fibrous Dysplasia of Bone and McCune-Albright Syndrome: A Bench to Bedside Review.
Hartley I; Zhadina M; Collins MT; Boyce AM
Calcif Tissue Int; 2019 May; 104(5):517-529. PubMed ID: 31037426
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment.
Ovejero D; Lim YH; Boyce AM; Gafni RI; McCarthy E; Nguyen TA; Eichenfield LF; DeKlotz CM; Guthrie LC; Tosi LL; Thornton PS; Choate KA; Collins MT
Osteoporos Int; 2016 Dec; 27(12):3615-3626. PubMed ID: 27497815
[TBL] [Abstract][Full Text] [Related]
6. Incidence and Prevalence of Fibrous Dysplasia/McCune-Albright Syndrome: A Nationwide Registry-Based Study in Denmark.
Meier ME; Vágó E; Abrahamsen B; Dekkers OM; Horváth-Puhó E; Rejnmark L; Appelman-Dijkstra NM
J Clin Endocrinol Metab; 2024 May; 109(6):1423-1432. PubMed ID: 38174586
[TBL] [Abstract][Full Text] [Related]
7. The Clinical Spectrum of McCune-Albright Syndrome and Its Management.
Spencer T; Pan KS; Collins MT; Boyce AM
Horm Res Paediatr; 2019; 92(6):347-356. PubMed ID: 31865341
[TBL] [Abstract][Full Text] [Related]
8. Fibrous Dysplasia/McCune-Albright Syndrome: A Rare, Mosaic Disease of Gα s Activation.
Boyce AM; Collins MT
Endocr Rev; 2020 Apr; 41(2):345-70. PubMed ID: 31673695
[TBL] [Abstract][Full Text] [Related]
9. Polyostotic Fibrous Dysplasia With and Without McCune-Albright Syndrome-Clinical Features in a Nordic Pediatric Cohort.
Utriainen P; Valta H; Björnsdottir S; Mäkitie O; Horemuzova E
Front Endocrinol (Lausanne); 2018; 9():96. PubMed ID: 29599748
[TBL] [Abstract][Full Text] [Related]
10. Murine models of HRAS-mediated cutaneous skeletal hypophosphatemia syndrome suggest bone as the FGF23 excess source.
Ovejero D; Michel Z; Cataisson C; Saikali A; Galisteo R; Yuspa SH; Collins MT; de Castro LF
J Clin Invest; 2023 May; 133(9):. PubMed ID: 36943390
[TBL] [Abstract][Full Text] [Related]
11. Fibrous dysplasia, phosphate wasting and fibroblast growth factor 23.
Imel EA; Econs MJ
Pediatr Endocrinol Rev; 2007 Aug; 4 Suppl 4():434-9. PubMed ID: 17982392
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a multilineage somatic mosaic RASopathy.
Lim YH; Ovejero D; Derrick KM; ; Collins MT; Choate KA
J Am Acad Dermatol; 2016 Aug; 75(2):420-7. PubMed ID: 27444071
[TBL] [Abstract][Full Text] [Related]
13. McCune-Albright syndrome: clinical picture and natural history in children and adolescents.
Völkl TM; Dörr HG
J Pediatr Endocrinol Metab; 2006 May; 19 Suppl 2():551-9. PubMed ID: 16789617
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic journey for individuals with fibrous dysplasia / McCune albright syndrome (FD/MAS).
Song K; Shrestha R; Delaney H; Vijjhalwar R; Turner A; Sanchez M; Javaid MK
Orphanet J Rare Dis; 2024 Feb; 19(1):50. PubMed ID: 38326833
[TBL] [Abstract][Full Text] [Related]
15. Burosumab treatment for fibrous dysplasia.
Gladding A; Szymczuk V; Auble BA; Boyce AM
Bone; 2021 Sep; 150():116004. PubMed ID: 33984553
[TBL] [Abstract][Full Text] [Related]
16. Outcome of Long-Term Bisphosphonate Therapy in McCune-Albright Syndrome and Polyostotic Fibrous Dysplasia.
Majoor BC; Appelman-Dijkstra NM; Fiocco M; van de Sande MA; Dijkstra PS; Hamdy NA
J Bone Miner Res; 2017 Feb; 32(2):264-276. PubMed ID: 27649526
[TBL] [Abstract][Full Text] [Related]
17. [McCune-Albright syndrome].
Miyoshi Y; Ozono K; Yamamoto T
Nihon Rinsho; 2005 Oct; 63 Suppl 10():534-8. PubMed ID: 16279696
[No Abstract] [Full Text] [Related]
18. Pharmacological Interventions Targeting Pain in Fibrous Dysplasia/McCune-Albright Syndrome.
Tucker-Bartley A; Selen DJ; Golden E; van Gool R; Ebb D; Mannstadt M; Upadhyay J
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768871
[TBL] [Abstract][Full Text] [Related]
19. Serum Phosphorus as a Driver of Skeletal Morbidity in Fibrous Dysplasia.
Gun ZH; Osamor C; Taylor J; Li X; Szymczuk V; Boyce AM
J Clin Endocrinol Metab; 2024 Apr; 109(5):1334-1340. PubMed ID: 37975816
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
